Eligibility for Anti-Amyloid Treatment

Dr. Gregg Day talks with Dr. Vijay Ramanan about the clinical trial eligibility criteria for lecanemab treatment for participants with early Alzheimer disease and the generalizability of anti-amyloid treatment.

Read the related article in Neurology.

Visit NPub.org/Podcast for associated article links.